In view of the evidence that DMXAA, acting via its effects on TAMs and/or dendritic cells, has the capacity to augment adaptive cytotoxic T cell anti-tumor activity, reviewed in [48], it would be of considerable interest to determine whether chronic administration of STING agonists might similarly lead to spontaneous immunity against 344SQ-ELuc metastases and primary lung adenocarcinomas. This evidence concerns the gene STING1 and neoplasm.